TRIGR Therapeutics, Inc. Company Profile

13:00 EST 21st January 2019 | BioPortfolio

TRIGR ( is a privately-owned company based in Irvine, California focused on the development and commercialization of novel therapeutics for unmet medical needs. TRIGR strives to be a global pharmaceutical company with a focus on the Pacific Rim region for clinical and commercial development. TRIGR is assembling a world-class management team that is based in the US and China/Hong Kong as it executes on the development of its programs together with its research collaboration partner, ABL Bio. TRIGR was founded by its current CEO George Uy, a biotech veteran who was responsible for the US launch of several anti-cancer drugs, including Xeloda® (Roche/Genentech) and Abraxane® (Abraxis/Celgene). George also recently launched the world’s first turmeric sparkling water, ARYA (The Heart of Turmeric)® Sparkling Water ( and currently partnered with LA Libations, a Coca-Cola venture-backed beverage incubator company.

News Articles [653 Associated News Articles listed on BioPortfolio]

ABL and TRIGR team up again in new immunotherapy development deal

Expanding upon a relationship spawned by a deal signed earlier this year, ABL Bio Inc. and TRIGR Therapeutics Inc. penned a new agreement, this time surrounding the development and commercialization o...

TRIGR and ABL Bio pen antibody deal worth over $550mm

TRIGR Therapeutics Inc. licensed global rights (excluding South Korea) to sell five of ABL Bio Corp.’s immunomodulatory antibodies for cancer.

TRIGR Therapeutics Licenses Oncology Asset from ABL Bio in $554.3 Million-Plus Deal

TRIGR Therapeutics, based in Irvine California, signed a deal with South Korean company ABL Bio Corporation. TIRGR is licensing the global commercial rights to ABL Bio’s pipeline of antibodies to tr...

Trigr acquires global rights to ABL Bio's antibody programs

Trigr Therapeutics acquired from ABL Bio global rights, excluding South Korea, to five of ABL's antibody programs: two immune -More- 

TRIGR Therapeutics, ABL Bio sign license deal for bispecific antibody candidate

The companies have entered into a collaboration and license agreement for TR009 (formerly known as ABL001 or NOV1501), an ABL developed bispecific antibody candidate targeting two important angiogenic...

Trigr gets rights to ABL's bispecific antibody

TRIGR Therapeutics Expands Bispecific Immuno-Oncology Pipeline with Exclusive Global License of Clinical Stage, Dual Angiogenesis Inhibitor from ABL Bio

TRIGR to lead clinical development of TR009, a dual VEGF/DLL4 BsAb showing early single agent activity in heavily pretreated, Avastin® and immunotherapy refractory patients with ...

M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin

Nabriva Therapeutics has completed the acquisition of Zavante Therapeutics for $97.5m. The acquisition will add the target company’s CONTEPO™ drug, which...Read More... The post M&As this we...

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [Kastle Therapeutics, LLC]


Olopatadine hydrochloride [Somerset Therapeutics, LLC]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [Breathe Easy Therapeutics, Inc]


Diclofenac sodium delayed release [Cambridge Therapeutics Technologies, LLC]

Diclofenac Sodium

Olopatadine hydrochloride [A-S Medication Solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [471 Associated PubMed Articles listed on BioPortfolio]

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro.

In recent times, co-delivery of therapeutics has emerged as a promising strategy for treating dreadful diseases such as cancer.

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Clinical Trials [169 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1292 Associated Companies listed on BioPortfolio]

TRIGR Therapeutics, Inc.

TRIGR ( is a privately-owned company based in Irvine, California focused on the development and commercialization of novel therapeutics for unmet medical ne...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "TRIGR Therapeutics, Inc." on BioPortfolio

We have published hundreds of TRIGR Therapeutics, Inc. news stories on BioPortfolio along with dozens of TRIGR Therapeutics, Inc. Clinical Trials and PubMed Articles about TRIGR Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of TRIGR Therapeutics, Inc. Companies in our database. You can also find out about relevant TRIGR Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Corporate Database Quicklinks

Searches Linking to this Company Record